Results 71 to 80 of about 6,719 (236)

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

open access: yesMolecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués   +3 more
wiley   +1 more source

OO-IB-MPRE: A Post-Quantum Secure Online/Offline Identity-Based Matchmaking Proxy Re-Encryption Scheme for Exercise Physiology Data

open access: yesMathematics
As smart education evolves, there is an increasing need for the cloud-centric management and sharing of student exercise physiological data gathered through wearable devices in the physical education domain.
You Zhao, Ye Song, Weiyi Song, Juyan Li
doaj   +1 more source

Name-Based Security for Information-Centric Networking Architectures

open access: yesFuture Internet, 2019
Information-Centric Networking (ICN) is an emerging communication paradigm built around content names. Securing ICN using named-based security is, therefore, a natural choice.
Nikos Fotiou, George C. Polyzos
doaj   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

Revocable hierarchical identity-based encryption

open access: yesTheoretical Computer Science, 2014
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
Seo, Jae Hong, Emura, Keita
openaire   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Secure Identity-Based Data Sharing and Profile Matching for Mobile Healthcare Social Networks in Cloud Computing

open access: yesIEEE Access, 2018
Cloud computing and social networks are changing the way of healthcare by providing realtime data sharing in a cost-effective manner. However, data security issue is one of the main obstacles to the wide application of mobile healthcare social networks ...
Qinlong Huang   +3 more
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Identity-Based Encryption [PDF]

open access: yes, 2011
Sanjit Chatterjee, Palash Sarkar
openaire   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy